Exome Sequencing for Atypical Femoral Fractures

• Status: Completed
• Trial end date: 2018-03-29
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to determine whether women who have atypical subtrochanteric and diaphyseal femoral fractures after treatment with bisphosphonates for osteoporosis, have a genetic predisposition to these unusual fractures.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Washington University School of Medicine
• Treatments: Diphosphonates; Etidronic Acid; Ibandronic Acid; Zoledronic Acid

Criteria

Inclusion Criteria:

• Female

• Previous and/or current use of bisphosphonate therapy for the management of osteoporosis

For inclusion in the fracture group must have:

-sustained one or more atypical subtrochanteric or diaphyseal femoral shaft fracture(s) as defined by the the 2010 ASBMR task force.

Exclusion Criteria:

• None